NCT02118610View on ClinicalTrials.gov

Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity

NACompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

June 30, 2019

Conditions
Schizophrenia
Interventions
DRUG

L-tetrahydropalmatine (30mg)

Active comparator

DRUG

Sugar pill

Placebo

Trial Locations (1)

21228

Maryland Psyciatric Research Center, Catonsville

All Listed Sponsors
collaborator

Stanley Medical Research Institute

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT02118610 - Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity | Biotech Hunter | Biotech Hunter